2003 Fiscal Year Final Research Report Summary
Mechanism of cancer metastasis via chemokine and its clinical application
| Project/Area Number |
14571140
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
General surgery
|
|---|
| Research Institution | Kyushu University |
|---|
Principal Investigator |
YOSHITAKE Shinichirou Kyushu Univ.Hospital, Research Associate, 大学病院, 助手 (80315142)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
MORI Masaki Medical Institute of Bioregulatlon Kyushu Univ., Professor, 生体防御医学研究所, 教授 (70190999)
|
|---|
| Project Period (FY) |
2002 – 2003
|
| Keywords | Fractalkine / CX3CR1 / colorectal cancer / CD3^+T lymphocyte / NK cell / RT-PCR |
|---|
| Research Abstract |
Local and systemic immune responses are impaired in patients with colorectal cancer (CRC) and it is known that the number of tumor infiltrating lymphocytes (TILs) is considerably a few. On the otherhand, some CRC cases that much TIL were observed, are better prognosis than those of few cases. However, it is ordinary that antigenisity make lymphocyte infiltration, it is possible that Fractalkine, one of chemoattractants, without antigenisity also recruit lymphocyte for tumor lesion. We made hypothesis that Fractalkine would recruit lymphocyte in the tumor and play on important role of antitumorimmunity. We analyzed therefore the expression level of Fractaikine in CRC cell lines as well as in clinical samples. The expression level of Fractaikine was correlated with the density of TIL. The CRC cases with strong Fractalkine expression showed better prognosis than those with weak expression. These data suggest that Fractalkineitiducedbythe tumorwouldrecruitlymphocyteto tumor site and these TILs would induce better prognosis. The expression level of Fractaikine was an essential biomarker for predicting prognosis of patient with CRC. Fractalkine was considered to be one the blomarker for the detection of the patients with high risk for recurrence, who might benefit from additional therapeutic strategies such as adjuvant therapy.
|
